ABS 205

Drug Profile

ABS 205

Alternative Names: ABS 200

Latest Information Update: 11 Dec 2002

Price : $50

At a glance

  • Originator University College Dublin
  • Developer American Biogenetic Sciences [CEASED]
  • Class
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Parkinson's disease; Schizophrenia

Most Recent Events

  • 25 Sep 2002 Discontinued - Preclinical for Schizophrenia in USA (unspecified route)
  • 25 Sep 2002 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route)
  • 25 Sep 2002 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top